Praxis Precision Medicines Reviews Unfavorable Outcomes from PRAX-114 Section 2/3 Monotherapy Aria Examine in Sufferers with Main Depressive Dysfunction

Praxis Precision Medicines, Inc.

Aria Examine didn’t obtain statistical significance on the first endpoint

Strategic realignment to focus sources on Motion Issues and Epilepsy franchises extends money runway into 2024

BOSTON, June 06, 2022 (GLOBE NEWSWIRE) — Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical firm translating genetic insights into the event of therapies for central nervous system (CNS) issues characterised by neuronal excitation-inhibition imbalance, right this moment introduced that the Section 2/3 Aria Examine evaluating the efficacy and security of PRAX-114 for monotherapy therapy of main depressive dysfunction (MDD) didn’t obtain statistical significance on the first endpoint of change from baseline within the 17-item Hamilton Despair Score Scale (HAM-D17) complete rating at Day 15, or on any secondary endpoints. Praxis intends to share detailed leads to an upcoming medical presentation or publication.

“We’re shocked and disillusioned within the Aria Examine outcomes,” stated Marcio Souza, president and chief government officer of Praxis. “PRAX-114 was well-tolerated within the Aria Examine, but the impact didn’t ship to satisfy the wants of sufferers. Praxis is dedicated to our mission to assist folks affected by CNS issues and can prioritize our packages in motion issues and epilepsy shifting ahead. We need to thank all the sufferers, investigators and companions who participated within the Aria Examine.”

The strategic realignment will lead to a discount of the Firm’s workforce and future working bills. On account of the realignment, the Firm’s money runway will now lengthen into 2024. The strategic alignment will deal with delivering Section 2b outcomes for PRAX-944 in important tremor (Essential1 Examine) and proof-of-concept for PRAX-562 in epilepsy and advancing the pre-clinical pipeline.

About Praxis
Praxis Precision Medicines is a clinical-stage biopharmaceutical firm translating genetic insights into the event of therapies for CNS issues characterised by neuronal excitation-inhibition imbalance. Praxis is making use of insights from genetic epilepsies to each uncommon and extra prevalent neurological and psychiatric issues, utilizing our understanding of shared organic targets and circuits within the mind. Praxis has established a broad portfolio with a number of packages, together with product candidates throughout psychiatric issues, motion issues and epilepsy, with three clinical-stage product candidates. For extra info, please go to and observe us on LinkedIn and Twitter.

Ahead-Wanting Statements

This press launch comprises forward-looking statements inside the which means of the Non-public Securities Litigation Reform Act of 1995 and different federal securities legal guidelines, together with specific or implied statements relating to our future expectations, plans and prospects, together with, with out limitation, statements relating to the event of our product candidates and our money runway. The specific or implied forward-looking statements included on this press launch are solely predictions and are topic to plenty of dangers, uncertainties and assumptions, together with, with out limitation: uncertainties inherent in scientific trials; our skill to provoke, enroll, conduct or full ongoing and deliberate scientific trials and our timelines for regulatory submissions; the anticipated timing of submissions for regulatory approval or evaluate by governmental authorities; dangers, uncertainties and assumptions relating to the impression of the persevering with COVID-19 pandemic on our enterprise, operations, technique, objectives and anticipated timelines of our ongoing and deliberate preclinical actions; and different dangers regarding our packages and operations as described in additional element in our Annual Report on Kind 10-Okay for the 12 months ended December 31, 2021, our Quarterly Reviews on Kind 10-Q and different filings made with the Securities and Trade Fee. Though our forward-looking statements mirror the great religion judgment of our administration, these statements are primarily based solely on info and elements at present recognized by us. In consequence, you might be cautioned to not depend on these forward-looking statements. Any forward-looking assertion made on this press launch speaks solely as of the date on which it’s made. We undertake no obligation to publicly replace or revise any forward-looking assertion, whether or not because of new info, future developments or in any other case.

CONTACT: Investor Contact: Alex Kane Praxis Precision Medicines [email protected] 617-300-8481 Media Contact: Ian Stone Canale Communications [email protected] 619-849-5388